

Lomustine and Bevacizumab 5mg/kg Therapy

INDICATIONS FOR USE:

INDICATION	ICD10	Regimen Code	HSE approved reimbursement status*
For the treatment of recurrent malignant glioblastoma	C71	00742a	N/A

*This is for post 2012 indications only

TREATMENT:

The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patients individual clinical circumstances

Bevacizumab is administered on days 1, 15 and 29, lomustine is administered on day 1 of a 42 day cycle for up to 6 cycles.

Facilities to treat anaphylaxis MUST be present when the systemic anti-cancer therapy (SACT) is administered.

Admin. Order	Day	Drug	Dose	Route	Diluent & Rate	Cycles
1	1, 15, 29	Bevacizumab	5mg/kg	IV infusion	100mL NaCl 0.9% over 90minutes ^{a, b}	Every 42 days
2	1	Lomustine ^c	90mg/m ² (max. recommended dose 160mg)	PO	N/A	Every 42 days

^a Flush line with NaCl 0.9% pre and post bevacizumab dose as it should not be mixed with glucose solutions.

^b The initial dose of bevacizumab should be delivered over 90 minutes as an intravenous infusion. If the first infusion is well tolerated, the second infusion may be administered over 60 minutes. If the 60-minute infusion is well tolerated, all subsequent infusions may be administered over 30 minutes. Alternatively, the unlicensed use of shorter infusion times¹ is described in the NCCP Bevacizumab Rapid Infusion Rate Guidance [here](#). It should not be administered as an intravenous push or bolus.

^c Lomustine is an unlicensed drug. If the drug is not to be dispensed by the hospital, then the hospital should ensure communication with the patient's community pharmacy to ensure there is no interruption in treatment.

ELIGIBILITY:

- Indication as above
- ECOG 0-2
- Adequate hematologic, renal and hepatic function

EXCLUSIONS:

- Hypersensitivity to bevacizumab, lomustine or any of the excipients

NCCP Regimen: Lomustine and Bevacizumab 5mg/kg Therapy	Published: 19/12//2022 Review: 19/01/2029	Version number: 3
Tumour Group: Neuro-oncology NCCP Regimen Code: 00742	ISMO Contributor: Prof Patrick Morris	Page 1 of 7

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens

- Recent intracranial haemorrhage
- Recent stroke or MI (less than 1 year)
- Major surgery within 4 weeks
- Imaging showing no or minimal contrast enhancement or evidence of gliomatosis cerebri
- Hypersensitivity to Chinese Hamster Ovary (CHO) cell products or other recombinant human or humanised antibodies
- Pregnancy
- Breast-feeding

USE WITH CAUTION:

- Previous pelvic radiotherapy
- Pre-existing uncontrolled hypertension
- Clinically significant cardiovascular disease
- Renal disease including proteinuria
- Bleeding/Clotting disorders
- Previous anthracycline exposure
- History of significant venous thromboembolism
- Recent (less than 6 months) arterial thromboembolic events
- Prior radiation to the chest wall or other serious medical illness

PRESCRIPTIVE AUTHORITY:

The treatment plan must be initiated by a Consultant Medical Oncologist

TESTS:

Baseline tests:

- FBC, renal and liver profile
- Dipstick urinalysis for protein
- Blood pressure measurement, cardiac assessment including history and physical exam
- ECHO should be considered as clinically indicated
- Blood glucose
- Pulmonary function tests as clinically indicated for patients considered high risk of pulmonary toxicity
- INR if clinically indicated*
*(For patients on warfarin, weekly INR until stable warfarin dose established, then INR prior to each cycle)

Regular tests:

- FBC, renal and liver profile, dipstick urinalysis for protein
- Blood pressure prior to each cycle and post treatment

NCCP Regimen: Lomustine and Bevacizumab 5mg/kg Therapy	Published: 19/12//2022 Review: 19/01/2029	Version number: 3
Tumour Group: Neuro-oncology NCCP Regimen Code: 00742	ISMO Contributor: Prof Patrick Morris	Page 2 of 7
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		

- Pulmonary function tests as clinically indicated
- INR if clinically indicated*
*(For patients on warfarin, weekly INR until stable warfarin dose established, then INR prior to each cycle).

Disease monitoring:

Disease monitoring should be in line with the patient’s treatment plan and any other test/s as directed by the supervising Consultant.

DOSE MODIFICATIONS:

- Any dose modification should be discussed with a Consultant
- Bevacizumab dose reduction for adverse events is not recommended (SmPC). If indicated, bevacizumab therapy should either be permanently discontinued or temporarily suspended until toxicity resolves (Table 3 and Table 4)

Haematological:

Table 1: Dose modifications for lomustine in haematological toxicity

ANC (x 10 ⁹ /L)		Platelets (x 10 ⁹ /L)	Dose
≥1.0	and	≥100	100%
<1.0	And/or	< 80	Delay lomustine treatment until ANC ≥1.0 and platelets ≥100. Consider dose reduction

Renal and Hepatic Impairment:

Table 2: Dose modification of lomustine and bevacizumab in renal and hepatic impairment

Drug	Renal Impairment	Hepatic Impairment										
Bevacizumab	Renal impairment: no need for dose adjustment is expected Haemodialysis: no need for dose adjustment is expected	Hepatic impairment: no need for dose adjustment is expected										
Lomustine	<table border="1"> <thead> <tr> <th>CrCl (ml/min)</th> <th>Dose</th> </tr> </thead> <tbody> <tr> <td>>50</td> <td>No dose adjustment is needed</td> </tr> <tr> <td>30-50</td> <td>75% of the original dose</td> </tr> <tr> <td><30</td> <td>Not recommended</td> </tr> <tr> <td>Haemodialysis</td> <td>Not recommended</td> </tr> </tbody> </table>	CrCl (ml/min)	Dose	>50	No dose adjustment is needed	30-50	75% of the original dose	<30	Not recommended	Haemodialysis	Not recommended	Mild and moderate: no need for dose adjustment is expected Severe: not recommended
CrCl (ml/min)	Dose											
>50	No dose adjustment is needed											
30-50	75% of the original dose											
<30	Not recommended											
Haemodialysis	Not recommended											

¹ Bevacizumab (renal and hepatic - Giraud et al);

² Lomustine (renal and hepatic - Giraud et al)

NCCP Regimen: Lomustine and Bevacizumab 5mg/kg Therapy	Published: 19/12//2022 Review: 19/01/2029	Version number: 3
Tumour Group: Neuro-oncology NCCP Regimen Code: 00742	ISMO Contributor: Prof Patrick Morris	Page 3 of 7

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens

Management of adverse events:

Proteinuria:

Table 3: Dose modifications of bevacizumab for proteinuria

Degree of proteinuria	Action
Neg or 1+ dipstick or less than 1 g/L laboratory urinalysis for protein	Administer bevacizumab dose as scheduled
2+ or 3+ dipstick or greater than or equal to 1 g/L laboratory urinalysis for protein	Administer bevacizumab dose as scheduled. Collect 24-hour urine for determination of total protein within 3 days before the next scheduled bevacizumab administration. Adjust bevacizumab treatment based on the table below
If urine dipstick shows 4+ at baseline or during treatment	Withhold bevacizumab and proceed with 24 hour urine collection
24-hour urine total protein (g/24hr)	Action
less than or equal to 2	Proceed
greater than 2 to 4	Hold dose and recheck 24 hour urine every 2 weeks, resume therapy when less than or equal to 2g/24hour
greater than 4	Discontinue Therapy

Table 4: Dose modification of bevacizumab for adverse events

Adverse reactions		Recommended dose modification
Hypertension	Uncontrolled* or symptomatic hypertension on Day 1	Withhold bevacizumab treatment and start antihypertensive therapy or adjust pre-existing medication
	Grade 2-3 hypertension	Initiate antihypertensive therapy and consider interruption of bevacizumab until controlled
	Grade 4 hypertension or persisting grade 3 hypertension	Discontinue bevacizumab
Grade 4 Proteinuria		Discontinue bevacizumab
Tracheoesophageal (TE) fistula or any Grade 4 fistula		Discontinue bevacizumab
Grade 4 Thromboembolic events		Discontinue bevacizumab
Haemorrhagic event ≥ Grade 3		Discontinue bevacizumab
Gastrointestinal Perforation		Discontinue bevacizumab
*Uncontrolled hypertension for initiating bevacizumab is defined as sustained BP>150/100mmHg while receiving anti-hypertensive medication		

NCCP Regimen: Lomustine and Bevacizumab 5mg/kg Therapy	Published: 19/12//2022 Review: 19/01/2029	Version number: 3
Tumour Group: Neuro-oncology NCCP Regimen Code: 00742	ISMO Contributor: Prof Patrick Morris	Page 4 of 7
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		

SUPPORTIVE CARE:

EMETOGENIC POTENTIAL:

Bevacizumab: Minimal **(Refer to local policy)**
 Lomustine: Moderate to High **(Refer to local policy)**

PREMEDICATIONS:

None usually required unless the patient has had a previous hypersensitivity.

OTHER SUPPORTIVE CARE:

Lomustine can cause birth defects. Men and women are recommended to take contraceptive precautions during therapy with lomustine and for 6 months after treatment.

ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS:

The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

Bevacizumab:

- **Gastrointestinal perforations:** Patients may be at an increased risk for the development of gastrointestinal perforation and gall bladder perforation when treated with bevacizumab. Intra-abdominal inflammatory process may be a risk factor for gastrointestinal perforations in patients with metastatic carcinoma of the colon or rectum, therefore, caution should be exercised when treating these patients. Therapy should be permanently discontinued in patients who develop gastrointestinal perforation.
- **Wound healing complications:** Bevacizumab may adversely affect the wound healing process. Therapy should not be initiated for at least 28 days following major surgery or until the surgical wound is fully healed. In patients who experienced wound healing complications during therapy, treatment should be withheld until the wound is fully healed. Therapy should be withheld for major elective surgery for 28 days and for 7 days for minor surgery or as directed by the prescribing Consultant. Necrotising fasciitis, including fatal cases, has rarely been reported in patients treated with bevacizumab. This condition is usually secondary to wound healing complications, gastrointestinal perforation or fistula formation. Bevacizumab therapy should be discontinued in patients who develop necrotising fasciitis, and appropriate treatment should be promptly initiated.
- **Hypertension:** An increased incidence of hypertension has been observed in patients treated with bevacizumab. Clinical safety data suggest that the incidence of hypertension is likely to be dose-dependent.
 - Pre-existing hypertension should be adequately controlled before starting bevacizumab treatment. Bevacizumab may be continued in conjunction with standard anti-hypertensive therapy at physician's discretion.
 - Patients should have their blood pressure measured before each dose or more frequently if hypertension develops/worsens.
 - Any patient who develops hypertension (>150/100 mmHg) should be treated with anti-

NCCP Regimen: Lomustine and Bevacizumab 5mg/kg Therapy	Published: 19/12//2022 Review: 19/01/2029	Version number: 3
Tumour Group: Neuro-oncology NCCP Regimen Code: 00742	ISMO Contributor: Prof Patrick Morris	Page 5 of 7
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		

hypertensive medications, or have their pre-existing medications adjusted. Patients developing severe hypertension (>200/110 mm Hg) that is not controlled with medication should have bevacizumab discontinued.

- It should be permanently discontinued if the patient develops hypertensive crisis or hypertensive encephalopathy.
- **Posterior Reversible Encephalopathy Syndrome (PRES):** There have been rare reports of bevacizumab-treated patients developing signs and symptoms that are consistent with PRES, a rare neurologic disorder, which can present with the following signs and symptoms among others: seizures, headache, altered mental status, visual disturbance, or cortical blindness, with or without associated hypertension. A diagnosis of PRES requires confirmation by brain imaging, preferably magnetic resonance imaging (MRI). In patients developing PRES, treatment of specific symptoms including control of hypertension is recommended along with discontinuation of bevacizumab. The safety of reinitiating therapy in patients previously experiencing PRES is not known.
- **Proteinuria:** Patients with a history of hypertension may be at increased risk for the development of proteinuria.
- **Thromboembolism:** Patients receiving bevacizumab plus chemotherapy, with a history of arterial thromboembolism or age > 65 years have an increased risk of developing arterial thromboembolic reactions during therapy. Caution should be taken when treating these patients. Therapy should be permanently discontinued in patients who develop arterial thromboembolic reactions. Patients may be at risk of developing venous thromboembolic reactions, including pulmonary embolism under bevacizumab treatment. Bevacizumab should be discontinued in patients with life-threatening (Grade 4) thromboembolic reactions, including pulmonary embolism. Patients with thromboembolic reactions ≤ Grade 3 need to be closely monitored.
- **Haemorrhage:** Patients treated with bevacizumab have an increased risk of haemorrhage, especially tumour associated haemorrhage and minor mucocutaneous haemorrhage. Bevacizumab should be used with caution in patients at risk of bleeding.
- **Aneurysms and artery dissections:** The use of VEGF pathway inhibitors in patients with or without hypertension may promote the formation of aneurysms and/or artery dissections. Before initiating bevacizumab, this risk should be carefully considered in patients with risk factors such as hypertension or history of aneurysm.

Lomustine:

- **Neutropenia:** Fever or other evidence of infection must be assessed promptly and treated appropriately.
- **Pulmonary toxicity:** Lomustine should be administered with caution in patients with a baseline below 70% of predicted forced vital capacity (FVC) or carbon monoxide diffusing capacity (DLCO.) Baseline pulmonary function studies should be carried out and repeated as clinically indicated during treatment. Pulmonary toxicity associated with lomustine appears to be dose- related.

DRUG INTERACTIONS:

- Current drug interaction databases should be consulted for more information.
- The safety and efficacy of concomitant administration of radiotherapy and bevacizumab has not been established.

NCCP Regimen: Lomustine and Bevacizumab 5mg/kg Therapy	Published: 19/12//2022 Review: 19/01/2029	Version number: 3
Tumour Group: Neuro-oncology NCCP Regimen Code: 00742	ISMO Contributor: Prof Patrick Morris	Page 6 of 7
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		

REFERENCES:

1. Gleeson JP, et al. Similar overall survival with reduced vs. standard dose bevacizumab monotherapy in progressive glioblastoma. *Cancer Med* 2020;9(2):469-475
2. Wick W, et al. Lomustine and Bevacizumab in Progressive Glioblastoma. *N Engl J Med* 2017; 377:1954-1963. Available <https://www.nejm.org/doi/full/10.1056/nejmoa1707358>
3. Giraud E L, Lijster B D, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment: an update. Available at: <https://pubmed.ncbi.nlm.nih.gov/37269847/>
4. NCCP | Bevacizumab Rapid Infusion Rate Guidance | V2 2021 available at <https://www.hse.ie/eng/services/list/5/cancer/profinfo/medonc/sactguidance/bevacizumab-rapid-infusion-rate-guidance.pdf>
5. NCCP Classification Document for Systemic Anti-Cancer Therapy (SACT) Induced Nausea and Vomiting. V5 2023. Available at: <https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/nccp-classification-document-for-systemic-anti-cancer-therapy-sact-induced-nausea-and-vomiting.pdf>
6. Bevacizumab (Avastin®) Summary of product characteristics EMA. Last updated 17/03/2023. Accessed December 2023. Available at https://www.ema.europa.eu/en/documents/product-information/avastin-epar-product-information_en.pdf
7. Lomustine BCCA Drug monograph Summary of Product Characteristics. Last updated 5/06/2018. Accessed December 2023 Available at http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Lomustine_monograph.pdf

Version	Date	Amendment	Approved By
1	19/12/2022		Prof Patrick Morris
2	15/05/2023	Amended treatment table and updated hypertension dose modifications for bevacizumab.	Prof Patrick Morris
3	19/01/2024	Reviewed. Dose modifications for renal and hepatic impairment updated in line with recommendations by Giraud at al, 2023.	Prof Patrick Morris

Comments and feedback welcome at oncologydrugs@cancercontrol.ie.

ⁱ The rapid infusion is an unlicensed means of administration of bevacizumab for the indication described above, in Ireland. Patients should be informed of this and consented to treatment in line with the hospital's policy on the use of unlicensed medication and unlicensed or "off label" indications. Prescribers should be fully aware of their responsibility in communicating any relevant information to the patient and also ensuring that the unlicensed or "off label" means of administration has been acknowledged by the hospital's Drugs and Therapeutics Committee, or equivalent, in line with hospital policy.

NCCP Regimen: Lomustine and Bevacizumab 5mg/kg Therapy	Published: 19/12//2022 Review: 19/01/2029	Version number: 3
Tumour Group: Neuro-oncology NCCP Regimen Code: 00742	ISMO Contributor: Prof Patrick Morris	Page 7 of 7
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		